(firstQuint)Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability.

 The primary objective of this study is to evaluate the systemic pharmacokinetics (PK) of LE (loteprednol etabonate ophthalmic gel), 0.

38% in normal healthy volunteer subjects at least 18 years of age and with a normal ophthalmic history.

 Systemic PK will be assessed in this study after a single dose and after 2 weeks of daily BID dosing.

.

 Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability@highlight

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, in Normal Healthy Volunteers